You have been a member here for less than a month. What your likely going to see are delays for various reasons mostly unknown. In order to reach .20 the stock must experience a 500% gain, doable in the sense that nothing is impossible, but as likely as Bigfoot being captured and caged. We all want to see the stock shoot up and hold ground but there are so many headwinds to overcome namely, getting rid of the toxic debt and achieving sufficient capital to continue clinical trials. Hopefully we will receive a better understanding of just how the R/S may play out but I have my doubts about whether I will like the details. The stock is trading to low for them to offer anything better than 1-200, 1-300. Of course, they may make a big announcement that gives us a pop although good news has often resulted in little or no positive stock activity.

We will just have to wait and see, nobody knows what is going to occur next.